We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Vertex Pharmaceuticals Inc. plans to raise up to $200 million in the coming
months to help fuel research and development, clinical trials and potential
acquisitions.
Impax Laboratories Inc. said it did not file its annual 10-K financial report
with the Securities and Exchange Commission by March 31, the end of a 15-day
extension granted by the SEC.
Invitrogen Corporation announced that it has completed its acquisition of Dynal
Biotech. Invitrogen acquired Dynal from majority owner Nordic Capital and a
co-investor in a cash transaction totaling approximately 2.5 billion NOK, or
approximately $391 million, based on foreign currency forward contracts executed
previously by Invitrogen.
Halozyme Therapeutics, a development stage biopharmaceutical
company focused on the development and commercialization of recombinant human
enzymes, and Baxter Healthcare Corporation announced that they have expanded
their relationship by signing a development and supply agreement for Enhanze
SC, Halozyme's recombinant human hyaluronidase enzyme (rHuPH20).
Teva Pharmaceutical has received tentative approval from the FDA to launch generic
versions of two blockbuster drugs -- Eli Lilly's antidepressant Zyprexa and Pfizer's
blood pressure medication Norvasc.
Investigators, sponsors and institutional review boards (IRBs) looking to reduce
the time it takes to conduct multicenter clinical research should consider implementing
a centralized IRB review process, suggests a new FDA draft guidance that describes
how to initiate the review strategy.
The FDA's premarketing and postmarketing safety programs
from drugs and biologics will be at the top of the agenda when the agency's
Science Board convenes this month.
Acting FDA Commissioner Lester Crawford is keeping the pressure on firms' direct-to-consumer
(DTC) advertising practices, as some pharmaceutical companies already are moving
to ensure their ads are more informative and balanced.
Cardiome Pharma Corp. announced that the underwriters of its recently completed
public offering have exercised their over-allotment option in full, purchasing
an additional 1,275,000 common shares for gross proceeds of approximately US$7.6
million.
Australian scientists have identified an enzyme that destroys cartilage in mice
and believe the find may lead to new drugs which stop cartilage joint deterioration
and painful arthritis in humans.